GSK And Medable Discuss The Next Phase Of DCTs

The Decentralized Trials & Research Alliance (DTRA) discussion emphasized GSK's strategic shift towards decentralized clinical trials (DCTs) to boost trial accessibility and improve health outcomes. GSK is actively incorporating technologies such as electronic Clinical Outcome Assessments (eCOAs), eConsent, and telehealth to make DCTs central to contemporary research practices. This shift is part of GSK's broader strategy to enhance trial accessibility, diversity, and efficiency through a comprehensive change management approach. They have engaged stakeholders and aligned decentralized modalities with strategic goals, establishing dedicated teams focused on compliance and efficiency.

Performance metrics have been crucial in securing leadership support, while communication and education have fostered a culture of learning within the organization. GSK emphasizes the importance of a robust accountability framework, clear role definitions, and continuous learning to successfully scale DCTs. The discussion also highlights the potential for collaboration with Medable's experts to further refine and enhance clinical trial strategies.